Pipeline
We are advancing our clinical-stage pipeline of differentiated treatments focused on chronic diseases with high unmet need around the globe, including cardiovascular, metabolic and pulmonary conditions.
Program
Indication
Drug Discovery / Preclinical
Phase 1
Phase 2
Oral GLP-1R Franchise
GSBR-1290
GSBR-2nd Gen
Type 2 Diabetes and Obesity
GSBR-3rd Gen
Oral APJR
ANPA-0073
Pulmonary Hypertension
ANPA-0073
Pulmonary Fibrosis
Oral LPAR1
LTSE
Pulmonary Fibrosis
Therapeutic Area Focus
Chronic diseases are rapidly increasing worldwide, escalating the demand for life-changing medicines. These conditions represent 73% of all deaths worldwide and 60% of the global burden of disease. At Structure, we are determined to transform these devastating figures with best-in-class, small molecule medicines.
463 Million
suffer from Type 2 Diabetes
46% increase by 2045
90% of T2DM patients are overweight or obese
150 Million
suffer from our cardiopulmonary disease areas of focus
>2x increase in incidence of pulmonary fibrosis over last 30 yrs
Mortality can occur within 3-5 yrs